chlorambucil has been researched along with Chromosomal Triplication in 4 studies
Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Few recurrent chromosomal abnormalities have been reported, and their prognostic value is not known." | 2.78 | Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia. ( Andrieux, J; Baranger, L; Barin, C; Bilhou-Nabera, C; Blons, H; Callet-Bauchu, E; Chapiro, E; Chevret, S; Chiesa, J; Daudignon, A; Eclache, V; Gachard, N; Grelier, A; Henry, C; Lambert, J; Leblondon, V; Lejeune, J; Luquet, I; Merle-Beral, H; Mossafa, H; Mould, S; Mozziconacci, MJ; Mugneret, F; Nguyen-Khac, F; Owen, R; Penther, D; Struski, S; Terre, C; Veronese, L, 2013) |
| "Elimination of minimal residual disease has been linked to improved survival and become an important clinical goal." | 2.43 | Chronic lymphocytic leukemia: current and emerging treatment approaches. ( Kay, NE; O'Brien, S; Rai, KR, 2006) |
| "The most common treatment of chronic lymphocytic leukemia (CLL) is the alkylating agent chlorambucil (CLB), with or without prednisone." | 1.32 | The effect of chlorambucil treatment on cytogenetic parameters in chronic lymphocytic leukemia patients. ( Amiel, A; Biton, I; Fejgin, MD; Gaber, E; Lishner, M; Yukla, M, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nguyen-Khac, F | 1 |
| Lambert, J | 1 |
| Chapiro, E | 1 |
| Grelier, A | 1 |
| Mould, S | 1 |
| Barin, C | 1 |
| Daudignon, A | 1 |
| Gachard, N | 1 |
| Struski, S | 1 |
| Henry, C | 1 |
| Penther, D | 1 |
| Mossafa, H | 1 |
| Andrieux, J | 1 |
| Eclache, V | 1 |
| Bilhou-Nabera, C | 1 |
| Luquet, I | 1 |
| Terre, C | 1 |
| Baranger, L | 1 |
| Mugneret, F | 1 |
| Chiesa, J | 1 |
| Mozziconacci, MJ | 1 |
| Callet-Bauchu, E | 1 |
| Veronese, L | 1 |
| Blons, H | 1 |
| Owen, R | 1 |
| Lejeune, J | 1 |
| Chevret, S | 1 |
| Merle-Beral, H | 1 |
| Leblondon, V | 1 |
| Oscier, DG | 1 |
| Rose-Zerilli, MJ | 1 |
| Winkelmann, N | 1 |
| Gonzalez de Castro, D | 1 |
| Gomez, B | 1 |
| Forster, J | 1 |
| Parker, H | 1 |
| Parker, A | 1 |
| Gardiner, A | 1 |
| Collins, A | 1 |
| Else, M | 1 |
| Cross, NC | 1 |
| Catovsky, D | 1 |
| Strefford, JC | 1 |
| Amiel, A | 1 |
| Biton, I | 1 |
| Yukla, M | 1 |
| Gaber, E | 1 |
| Fejgin, MD | 1 |
| Lishner, M | 1 |
| Kay, NE | 1 |
| Rai, KR | 1 |
| O'Brien, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Trial Comparing the Efficacy of Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia,Lymphoplasmacytic Lymphoma or Splenic Marginal Zone Lymphoma[NCT00566332] | Phase 3 | 414 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| A Randomised Trial of Chlorambucil Versus Fludarabine as Initial Therapy of Waldenström's Macroglobulinaemia and Splenic Lymphoma With Villous Lymphocytes[NCT00608374] | Phase 3 | 400 participants (Anticipated) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for chlorambucil and Chromosomal Triplication
| Article | Year |
|---|---|
Chronic lymphocytic leukemia: current and emerging treatment approaches.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antine | 2006 |
2 trials available for chlorambucil and Chromosomal Triplication
| Article | Year |
|---|---|
Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chlorambucil; Chromosome Aberrations; Chromos | 2013 |
Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chlorambucil; Chromosome Aberrations; Chromos | 2013 |
Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chlorambucil; Chromosome Aberrations; Chromos | 2013 |
Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chlorambucil; Chromosome Aberrations; Chromos | 2013 |
The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.
Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineopla | 2013 |
1 other study available for chlorambucil and Chromosomal Triplication
| Article | Year |
|---|---|
The effect of chlorambucil treatment on cytogenetic parameters in chronic lymphocytic leukemia patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chlorambucil; Chromosome Aberrations; Ch | 2003 |